Osteoporosis treatment: Raloxifene (Evista) and stroke mortality

CMAJ. Canadian Medical Association Journal

Volumn 175, Issue 2, 2006, Pages 147-148

  Wooltorton, Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PHOSPHONIC ACID DERIVATIVE; RALOXIFENE; BONE DENSITY CONSERVATION AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CANCER RISK; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BINDING; DRUG EFFECT; HEART DISEASE; HOT FLUSH; HUMAN; INCIDENCE; LEG CRAMP; LUNG EMBOLISM; MORTALITY; OSTEOPOROSIS; PHLEBITIS; POSTMENOPAUSE; RISK FACTOR; SHORT SURVEY; STROKE; VEIN THROMBOSIS; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; FEMALE;

AGED; BONE DENSITY CONSERVATION AGENTS; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; OSTEOPOROSIS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33746197958     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060781     Document Type: Short Survey

References (1)

1. Associatíon of Evista (raloxifene hydrochloride) with increased risk of mortality due to stroke in postmenopausal women at increased risk for cardiovascular disease: preliminary results from the RUTH trial [Dear Health Care Professional letter]. Toronto: Eli Lilly Canada Inc.; 2006 May 18. Avialable: www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2006 /evista_hpc-cps_e.html (accessed 2006 Jun 20).